Zhi-Ming Shao

机构：Fudan University Shanghai Cancer Center, Qilu Hospital of Shandong University

发表论文 8 篇 · 总被引 750 次 · h-index 4

代表论文

• Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer (2022 · Annals of Oncology · 被引 461)
• Understanding breast cancer complexity to improve patient outcomes: The St Gallen International Consensus Conference for the Primary Therapy of Individuals with Early Breast Cancer 2023 (2023 · Annals of Oncology · 被引 233)
• LBA21 First-line (1L) datopotamab deruxtecan (Dato-DXd) vs chemotherapy in patients with locally recurrent inoperable or metastatic triple-negative breast cancer (mTNBC) for whom immunotherapy was not an option: Primary results from the randomised, phase III TROPION-Breast02 trial (2025 · Annals of Oncology · 被引 26)
• Chimeric Peptide-Engineered Polyprodrug Enhances Cytotoxic T Cell Response by Inducing Immunogenic Cell Death and Upregulating Major Histocompatibility Complex Class I (2024 · ACS Nano · 被引 14)
• 23P In vivo multi-dimensional CRISPR screens identify LGALS2 as an immunotherapy target in triple-negative breast cancer (2022 · Annals of Oncology · 被引 1)
• 333P: Safety and effectiveness of adebrelimab as second- or later-line treatment in extensive-stage small-cell lung cancer: A prospective, real-world study (2025 · Journal of Thoracic Oncology)